What is a peptide–drug conjugate (PDC)?
Peptide–drug conjugates (PDCs) are hybrid molecules in which a biologically active
small-molecule drug payload is covalently linked to a peptide carrier
through a defined chemical linker. By combining the targeting, binding, or transport properties of
peptides with the pharmacological activity of small-molecule drugs, PDCs are widely explored as a
strategy to improve selectivity, delivery, and functional profiling of therapeutic agents during
research and early development.
In a typical PDC design, the peptide component may serve as a targeting ligand,
cell-penetrating element, or spatial scaffold, while the drug payload
provides the desired biological activity. The linker chemistry—whether stable or
cleavable—plays a critical role in controlling conjugate stability, release behavior,
and overall molecular architecture. As a result, successful PDC development depends on careful
coordination of peptide sequence design, attachment site selection,
linker strategy, and payload compatibility.
Flexible Conjugation Chemistry
Cleavable & non-cleavable linkers
ISO 9001:2015/ISO 13845:2016
45+ Years of Expertise
U.S. Facilities (Texas)
Bio-Synthesis provides custom peptide–drug conjugation services to support
discovery-stage and preclinical PDC programs. Our approach is
design-led and payload-aware, with each project planned around the
chemical properties of the drug, the functional requirements of the peptide, and the intended
downstream application. We support a broad range of therapeutic small-molecule payloads—including
oncology drugs, antibiotics, antivirals, and other
bioactive compounds—using site-defined conjugation strategies to minimize heterogeneity
and improve reproducibility.
Bio-Synthesis workflows are tailored to deliver chemically defined PDCs suitable for
structure–function studies, payload comparison, and
optimization campaigns. Conjugation routes are selected to preserve payload integrity
and peptide functionality, with purification and fit-for-purpose analytical characterization
(e.g., HPLC/UPLC and LC-MS when feasible) aligned to research and development needs.
By integrating custom peptide synthesis, conjugation chemistry, and analytical support within a single platform, Bio-Synthesis peptide drug conjugation capabilities enable researchers to efficiently design, build, and evaluate peptide–drug conjugates as part of therapeutic research and early development programs.
Payload-driven design
We plan conjugation around drug functional groups, stability, and the desired exposure/release model.
Linker strategy
Choose stable vs cleavable chemistry based on whether intracellular payload release is required.
Analytical verification
Confirm identity/purity by HPLC/UPLC and LC-MS when feasible; report conversion/loading as appropriate.
Schematic representation of a peptide–drug conjugate (PDC) composed of a targeting peptide, linker, and drug payload.